The pages of Medical Device Daily are chock-full of outstanding content, but here are three stories from the month of April that caught my eye. Taking the eye out of ouch Seventh Sense Biosystems announced a registration trial for its TAP (touch-activated phlebotomy) device, which is one of those things that in times gone by was strictly the stuff of science fiction television shows. As my colleague Amanda Pedersen wrote in the April 3 edition, the TAP makes use of microneedles to obtain blood from the capillaries, and can dispense a...

Natera (San Carlos, California) has completed a $54.6 million financing round to support the expansion and continued global rollout of its non-invasive prenatal test, Panorama. The test uses fetal cell-free DNA found in maternal blood and works as early as nine weeks gestation, without risk to the fetus.